Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 73-83

  Ichhpujani, Parul ^a,b   Jay Katz, L ^a  

^a WILLS EYE HOSPITAL   (United States)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Dorzolamide; Glaucoma; Ocular hypertension; Timolol

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; CARBONATE DEHYDRATASE II; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A2; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PILOCARPINE; TIMOLOL; TIMOLOL MALEATE; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

AQUEOUS HUMOR; ASTHMA; ATRIOVENTRICULAR BLOCK; BETA ADRENERGIC RECEPTOR BLOCKING; BLURRED VISION; CARDIOGENIC SHOCK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENZYME INHIBITION; EYE BLOOD FLOW; EYE BURNING; EYE DISCOMFORT; EYE IRRITATION; EYE PAIN; GLAUCOMA; HEART FAILURE; HUMAN; HYPERCHLOREMIC ACIDOSIS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MORNING DOSAGE; OPEN ANGLE GLAUCOMA; PSEUDOEXFOLIATIVE GLAUCOMA; REVIEW; SINUS BRADYCARDIA; TASTE DISORDER;

EID: 77955508380     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s9757     Document Type: Review

References (70)

1. Vijaya L, George R, Paul PG, et al. Prevalence of open-angle glaucoma in a rural South India population. Invest Ophthalmol Vis Sci. 2005;46:4461-4467.
2. Iwase A, Suzuki Y, Araie M, et al; Tajimi Study Group, Japan Glaucoma Society. The Prevalence of Primary Open-Angle Glaucoma in Japanese: The Tajimi Study. Ophthalmology. 2004;111: 1641-1648.
3. Leske CM. Open-angle glaucoma an epidemiologic overview. Ophthalmic Epidemiol. 2007;14:166-172.
4. Sakata K, Sakata LM, Sakata VM, et al. Prevalence of glaucoma in a South Brazilian population: Projeto Glaucoma. Invest Ophthalmol Vis Sci. 2007;48:4974-4979.
5. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
6. Astrom S, Stenlund H, Linden C. Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: Results after 21 years of follow-up. Acta Opthalmol Scand. 2007;85:832-837.
7. Anton A, Andrada MT, Mujica V, Calle MA, Portela J, Mayo A. Prevalence of primary open-angle glaucoma in a spanish population: The Segovia Study. J Glaucoma. 2004;13:371-376.
8. Quigley H, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
9. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15:119-126.
10. The Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension. http://www.rcophth.ac.uk. Accessed Dec 10, 2009.
11. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22:1-21.
12. Hoyng PFJ, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs. 2000;59:411-434.
13. Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009;25:2543-2547.
14. Yeh J, Kravitz D, Francis B. Rational use of the fixed combination of dorzolamide-timolol in the management of raised intraocular pressure and glaucoma. Clin Ophthalmol. 2008;2:389-399.
15. Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging. 1997;10:384-403.
16. Heel RC, Brogden RN, Speight TM, et al. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs. 1979;17:38-55.
17. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retinal Eye Res. 2000;19: 87-112.
18. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol. 1978;96: 2045-2048.
19. Sonntag JR, Brindley GO, Shields MB. Effect of timolol therapy on outflow facility. Invest Ophthalmol Vis Sci. 1978;17:293-296.
20. Zimmerman TJ, Harbin R, Pett M, et al. Timolol and facility of outflow. Invest Ophthalmol Vis Sci. 1977;16:623-624.
21. Phylactos AC. Timolol inhibits adenylate cyclase activity in the iris-ciliary body and trabecular meshwork of the eye and blocks activation of the enzyme by salbutamol. Acta Ophthalmol (Copenh). 1986;64:613-622.
22. Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000;17:477-496.
23. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207-218.
24. Hasegawa T, Hara K, Hata S. Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos. 1994;22:377-382.
25. Wong BK, Bruhin PJ, Barrish A, et al. Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction. Drug Metab Dispos. 1996;24:659-663.
26. Maren TH, Conroy CW, Wynns GC, et al. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1997;13: 23-30.
27. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111:1343-1350.
28. Strahlman E, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one year extension. Dorzolamide Dose-Response Study Group Am J Ophthalmol. 1996;122:183-194. Erratum: Am J Ophthalmol. 1996;122:928.
29. Biollaz J, Munafo A, Buclin T, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47:453-460.
30. Martens-Lobenhoffer J, Banditt P. Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet. 2002;41:197-205.
31. Siesky B, Harris A, Brizendine E, et al. Literature review and meta analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol. 2009;54:33-46.
32. Januleviciene I, Harris A, Kagemann L, et al. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand. 2004;82: 730-737.
33. Manni G, Centofanti M, Gregori D, et al. The pulsatile ocular blood flow behaviour in open angle glaucoma patients after replacing timolol therapy with timolol and dorzolamide fixed combination: preliminary study. Acta Ophthalmol Scand. 2002;236:55-56.
34. Martinez A, Sanchez M. A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr Med Res Opin. 2006;22:67-73.
35. Harris A, Jonescu-Cuypers CP, Kagemann L, et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am J Ophthalmol. 2001;132: 490-495.
36. Rolle T, Tofani F, Brogliatti B, Grignolo FM. The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients. Eye (Lond). 2008;22:1172-1179.
37. Fuchsjager-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89: 1293-1297.
38. Galassi F, Sodi A, Renieri G, et al. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica. 2002;216:123-128.
39. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105:1952-959.
40. Boyle JE, Ghosh K, Gieser DK, et al; A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzo lamide-Timolol Study Group. Ophthalmology. 1998;105:1945-1951.
41. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand. 2004;82:42-48.
42. Susanna R Jr, Sheu WP. Comparison of latanoprost with fixed combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther. 2004;26:755-768.
43. Honrubia FM, Larsson LI, Spiegel D, et al. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand. 2002;80:635-641.
44. Konstas AG, Papapanos P, Tersis I, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110:1357-1360.
45. Orzalesi N, Rissetti L, Bottoli A. The effect of latanoprost, brimonidinee and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121:453-457.
46. Ozturk F, Ermis S, Inan U. Comparison of ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6 month study. Acta Ophthalmol Scand. 2007;85:80-83.
47. Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, ran-domized, masked, cross-over design study. Oftalmologia. 2005;49:39-45.
48. Parmaksiz S, Yuksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73-80.
49. Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology. 2003;110:2362-2368.
50. Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol. 2005;15:336-342.
51. Suzuki ERJ, Franklin LM, da Silva LJ, et al. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22:1799-1805.
52. Day DG, Schacknow CJ, Wand M, et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open angle glaucoma or ocular hypertension. Am J Ophthalmol. 2003;135:138-143.
53. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82:1249-1253.
54. Strohmaier K, Snyder E, DuBiner H, et al; The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105:1936-1944.
55. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidinee and timolol: six-month comparison of efficacy and tolerability. Ophthalmology. 2003;110:615-624.
56. Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidinee and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma. 2004;13:149-157.
57. Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidinee-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009:25 1645-1653.
58. Arcieri ES, Pereira ACA, Andreo EGV, et al. Fixed combination brimonidinee-timolol (Combigan) versus fixed combination dorzolamide-timolol (Cosopt) each given twice daily to reduce intraocular pressure in subjects with glaucoma or ocular hypertension [abstract no. E434-B169]. Invest Ophthalmol Vis Sci. 2006:47.
59. Zabriskie N, Netland PA. Comparison of brimonidinee/latanoprost and timolol/dorzolamide: two randomized, double masked, parallel clinical trials. Adv Ther. 2003;20:92-100.
60. Sverrisson T, Gross R, Pearson J, et al. The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group. J Glaucoma. 1999;8:315-324.
61. Kalzuny J, Szaflik J, Czechowicz-Janicka K. Timolol 0.5%/ dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open angle glaucoma or ocu\1lar hypertensive patients. Acta Ophthalmol Scand. 2003;81: 349-354.
62. Shin DH, Feldman RM, Sheu WP. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111: 276-282.
63. Konstas AG, Kozobolis VP, Lallos N, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/ timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye. 2004;18:1264-1269.
64. Cvenkel B, Stewart JA, Nelson LA, Stewart WC. Dorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Curr Eye Res. 2008;33:163-168.
65. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18:293-300.
66. Mundorf TK, Rauchman SH, Williams RD, Notivol R. Brinzo lamide/Timolol Preference Study Group. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2:623-628.
67. Teus MA, Miglior S, Laganovska G, et al. Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:629-636.
68. Hatanaka M, Reis A, Sano ME, Susanna R Jr. Additive Intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/ dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. J Glaucoma. 2009 Sep 2. [Epub ahead of print].
69. Fechtner RD, McCarroll KA, Lines CR, et al. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther. 2005; 21:242-249.
70. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glau\1coma: a systematic classification. J Glaucoma. 2003; 12:393-398.